Isoproterenol challenge of Hek-B2 cells causes a transient recruitment of the endogenous PDE4D isoforms found in these cells, namely PDE4D3 and PDE4D5, to the membrane fraction. PDE4D5 provides around 80% of the total PDE4D protein so recruited, although it only comprises about 40% of the total PDE4D protein in Hek-B2 cells. PDE4D5 provides about 80% of the total PDE4D protein found associated with ␤-arrestins immunopurified from Hek-B2, COS1, and A549 cells as well as cardiac myocytes, whereas its overall level in these cells is between 15 and 50% of the total PDE4D protein. Truncation analyses indicate that two sites in PDE4D5 are involved in mediating its interaction with ␤-arrestins, one associated with the common PDE4 catalytic region and the other located within its unique amino-terminal region. Truncation analyses indicate that two sites in ␤-arrestin 2 are involved in mediating its interaction with PDE4D5, one associated with its extreme amino-terminal region and the other located within the carboxylterminal domain of the protein. We suggest that the unique amino-terminal region of PDE4D5 allows it to preferentially interact with ␤-arrestins. This specificity appears likely to account for the preferential recruitment of PDE4D5, compared with PDE4D3, to membranes of Hek-B2 cells and cardiac myocytes upon challenge with isoproterenol.
The heptahelical ␤-adrenergic receptors (␤ 2 ARs) 1 act by coupling through the G-protein G s to stimulate adenylyl cyclase and thereby increase intracellular cAMP concentrations (1) (2) (3) (4) . It is now well established that the rapid uncoupling of this response is achieved by the action of the G-protein receptorcoupled kinase 2 (2) . This phosphorylates the carboxyl-terminal tail of the plasma membrane-associated ␤ 2 AR, allowing the recruitment of ␤-arrestins from the cytosol (5-7). It is this recruitment of ␤-arrestin, rather than phosphorylation per se, that elicits uncoupling, presumably by sterically blocking coupling of the ␤ 2 AR to G s . The importance of ␤-arrestin interaction to G-protein-coupled receptors (GPCRs) in vivo has been clearly established in knockout mouse models (8 -10) .
The attenuation of cAMP signaling is also achieved through the action of phosphodiesterases (PDEs) that are able to hydrolyze cAMP to 5Ј-AMP (11) (12) (13) (14) (15) (16) (17) . Since they provide the sole route for degradation of cAMP in cells, they are poised to play a key role in controlling cAMP signaling. Multiple genes encode a large superfamily of PDEs, which differ in their regulatory and kinetic properties. Of these, the PDE4 cAMP-specific phosphodiesterase family (13) (14) (15) (16) has recently attracted much interest, since PDE4-selective inhibitors are currently being developed as potential therapeutic agents for various inflammatory diseases of the respiratory system, such as asthma and chronic obstructive pulmonary disease (18 -21) . The PDE4 enzyme family is encoded by four genes (PDE4A, -B, -C, and -D), which generate over 16 different isoforms through the use of distinct promoters and alternative mRNA splicing (12, 13, 15, 22) . The various PDE4 isoforms, which often have very different patterns of expression in tissues, are each characterized by a unique amino-terminal region. The amino-terminal regions of each of the various PDE4 isoforms have been shown to be involved, in a number of instances, in determining their intracellular targeting and interaction with other proteins. The four PDE4 subfamilies can each be divided into the so-called long isoforms, which possess both the upstream conserved region 1 (UCR1) and upstream conserved region (UCR2) regulatory modules (22) (23) (24) , whereas the short isoforms lack UCR1 and the supershort isoforms both lack UCR1 and have a truncated UCR2 (12, 13, 15) .
Recently, a new feature of the G-protein receptor-coupled kinase/␤-arrestin desensitization system, associated with the ␤ 2 AR, has been demonstrated. Both ␤-arrestin 1 and ␤-arrestin 2 have been shown to bind to PDE4 isoforms from all four subfamilies (25) . This interaction allows ␤-arrestin to cause an agonist-dependent increase in cAMP degradation in the environs of the ␤ 2 AR, by recruiting PDE4 isoforms to the ␤ 2 AR. The recruited PDE4 appears able to regulate the activity of cAMPdependent protein kinase at the plasma membrane and thereby regulate the cAMP-dependent protein kinase phosphorylation status of the ␤ 2 AR itself (25, 26) . Through this action, the recruited PDE4 serves to regulate the ability of the ␤ 2 AR to switch between activation of adenylyl cyclase through G s and activation of extracellular signal-regulated kinase through G i (26) .
The long PDE4D3 and PDE4D5 isoforms, which differ only in having different unique amino-terminal regions, provide the major PDE4 activity in many cell types. Here we show that PDE4D5 is preferentially recruited over PDE4D3 for interaction with ␤-arrestins and suggest that this difference is attributable to a subregion found within the isoform-specific aminoterminal region of PDE4D5.
EXPERIMENTAL PROCEDURES

Materials-[
3 H]cAMP was from Amersham Biosciences. Bradford reagent was from Bio-Rad. Monoclonal antibodies specific to each of the four PDE4 subfamilies were a kind gift from Dr. Sharon Wolda (ICOS Corp.), as described previously (27) (28) (29) (30) . Hek-B2 cells were a kind gift from Prof. Graeme Milligan (University of Glasgow) (31) .
Mammalian Cell Expression Constructs-The full-length cDNAs encoding human PDE4D3 (GenBank TM L20970) and PDE4D5 (GenBank TM AF012073) as well as various truncated constructs of PDE4D5, all with a carboxyl-terminal VSV epitope tag, were cloned into pcDNA3 (Invitrogen) for expression in mammalian cells under the control of the cytomegalovirus intermediate early gene promoter, as we have reported previously (27, 32) . pcDNA3NARB2FLAG, encoding human wild type, carboxyl-terminal FLAG epitope-tagged ␤-arrestin 2 in pcDNA3, was used as described previously (25) .
Cell Culture-Hek293 and Hek293 cell lines stably overexpressing FLAG-tagged ␤ 2 AR-GFP (Hek-B2 cells), were cultured as described previously (25, 26, 31) . Preparation and short term culture of neonatal rat ventricular myocytes was as described by others, where 24 h after plating they were placed in low serum medium (33, 34) . COS1 cells were cultured as described previously (27) . A549 cells were cultured as described previously by others (35) . Transfection of Hek293 cells, Hek-B2 cells, and COS1 cells was done using Polyfect (Qiagen), following the manufacturer's instructions.
Membrane Recruitment of PDE4D Isoforms-Hek-B2 cells were stimulated with isoproterenol (10 M) for the indicated times before being washed three times in ice-cold KHEM buffer (50 mM KCl, 50 mM Hepes, pH 7.2, 10 mM EGTA, 1.92 mM MgCl 2 ). Cells were then harvested and homogenized before being centrifuged at 1,300 ϫ g for 10 min to yield low speed pellet (P1) and supernatant (S1) fractions. The S1 fraction was then centrifuged at 100,000 ϫ g for 30 min to yield a high speed supernatant (S2) and pellet (P2) fraction. Membrane fractions were then washed in KHEM buffer to remove any supernatant. 50 g of membrane protein from each time point was run on SDS-PAGE gels, transferred to nitrocellulose, and immunoblotted with a monoclonal PDE4D-specific antibody (27) .
Immunoprecipitation Studies to Evaluate the Interaction of Endogenous ␤-Arrestin and PDE4D Isoforms in Various Cell
Types-Cells were washed in KHEM buffer, harvested, homogenized, and fractionated as described above. Immunoprecipitation of endogenous ␤-arrestin was done by preclearing the S2 fraction (500-g protein) with 50 l of KHEM-washed protein A beads (Amersham Biosciences) before the addition of either 5 l of polyclonal antibody against ␤-arrestin (A1CT) (25) or 5 l of preimmune serum. The tubes were incubated at 4°C with end-over-end mixing for 1 h before the addition of 50 l of protein A beads. The tubes were mixed for a further 2 h at 4°C before the beads were pelleted at 1,300 ϫ g for 3 min. The beads were washed three times in KHEM buffer before being boiled in Laemmli buffer (36) . The immunoprecipitates and lysate (one-twentieth total lysate) were run on SDS-PAGE gels, transferred to nitrocellulose, and immunoblotted with the PDE4D monoclonal antibody. Each experiment was carried out on three separate occasions, and the amount of PDE4D3 and PDE4D5 that co-immunoprecipitated with ␤-arrestin was quantified by densitometry.
Immunoprecipitation Studies to Evaluate the Interaction between Recombinant ␤-Arrestin 2 and PDE4D5 Constructs in Transfected Cells-Hek293 or COS1 cells were co-transfected with one of the following ␤-arrestin 2 constructs: pcDNA3NARB2FLAG, encoding wild type, carboxyl-terminal FLAG-tagged ␤-arrestin 2 or various derivatives of this plasmid that encode truncations or "point" ␤-arrestin 2 mutants plus one of the following PDE4D constructs: 1) pCIneo-PDE4D3, encoding wild type, carboxyl-terminal VSV-tagged PDE4D3; 2) pcDNAPDE4D5VSV, encoding wild type, VSV-tagged PDE4D5; or 3) various pcDNA3 constructs encoding VSV-tagged, amino-terminal truncated forms of PDE4D5, as described previously by us (32, 37) . Transfections were typically performed with 10 g of plasmid DNA per 100-mm dish. However, to ensure that the ratio of the expression of PDE4D5-VSV and ␤-arrestin 2-FLAG were similar in each cell preparation, we performed parallel transfections in which we varied the amount of plasmid DNA (for both PDE4D5-VSV and ␤-arrestin 2-FLAG) transfected into the cells. After 48 h, the cells were harvested and lysed with 10 strokes of a 26 1 ⁄2-gauge needle in 500 l of KHEM buffer containing 1 mM dithiothreitol and Complete protease inhibitor mixture (Roche Applied Science). Cell debris was removed by centrifugation at 1,300 ϫ g for 10 min at 4°C. The expression of PDE4D5-VSV and ␤-arrestin 2-FLAG in each preparation was monitored by immunoblotting with an anti-VSV monoclonal antibody or the M2 anti-FLAG monoclonal antibody (both from Sigma), and densitometry was used to compare VSV or FLAG immunoreactivity. Cell lysates that contained expression ratios that were equal to or up to 10% greater than the control were selected for immunoprecipitations. For the immunoprecipitations, a volume of each lysate calculated to contain an equal amount of VSV immunoreactive material was then incubated with 40 l of anti-FLAG M2-agarose affinity gel (Sigma) for 2 h with end-over-end mixing at 4°C. The beads were pelleted by centrifugation and washed three times in KHEM buffer plus 0.05% Igepal detergent (Sigma). Protein complexes were released by boiling the beads in Laemmli buffer, and the co-immunoprecipitation of transfected PDE4s with ␤-arrestin 2-FLAG was analyzed by immunoblotting with anti-VSV monoclonal antibody and anti-FLAG antibody.
Expression of Fusion Proteins in Escherichia coli-For bacterial expression of PDE4D5, full-length PDE4D5 was cloned into pMALc2 (New England Biolabs) to generate pMALPDE4D5, which expresses MBP-PDE4D5, a fusion between maltose-binding protein (MBP) and PDE4D5 (32) . Full-length human ␤-arrestin 1 was cloned into pGEX-5X-3 (Amersham Biosciences) to generate pGEX-ARB1, which expresses GST-ARB1, a fusion protein between glutathione S-transferase (GST) and ␤-arrestin 1. Full-length ␤-arrestin 1 was cloned into pET15b (Novagen) to generate pETARB1, which expresses ␤-arrestin 1 with hexahistidine fused to its carboxyl-terminal end (His-ARB1). Cultures of E. coli BL21star cells (Invitrogen) containing pMALPDE4D5, pETARB1, pGEX-ARB1, or pGEX-5X-3 were grown to an A 600 of 0.6 and then induced with 0.2-1.0 mM isopropyl-␤-D-thiogalactopyranoside (Roche Applied Science) and grown for a further 4 h at 30°C. Bacteria were harvested by centrifugation at 4,000 ϫ g for 10 min at 4°C, and the bacterial pellets were frozen at Ϫ80°C overnight. His-ARB1 was purified from bacteria expressing pETARB1 using His-Bind Quick Columns (Novagen) according to the manufacturer's instructions. To purify the other recombinant proteins, the remaining pellets were resuspended in 10 ml of ice-cold resuspension buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 10 mM ␤-mercaptoethanol, and Complete protease inhibitor mixture) and sonicated 4 ϫ 30 s on ice. Triton X-100 was added to a final concentration of 0.02%, and cell debris was removed by centrifugation at 10,000 ϫ g for 10 min at 4°C. The cleared lysate was incubated with one-tenth volume of pre-equilibrated glutathione-Sepharose beads (Amersham Biosciences) for GST fusions or amylose resin (New England BioLabs) for MBP fusions for 1 h end-overend at 4°C. The beads were collected by centrifugation at 2,000 ϫ g for 1 min and washed three times with resuspension buffer. The fusion proteins were eluted by the addition of 10 mM glutathione, 50 mM Tris-HCl, pH 8.0, for GST fusions or 10 mM maltose, 50 mM Tris-HCl, pH 8.0, for MBP fusions. The fusion proteins were dialyzed three times against 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5% glycerol and then stored at Ϫ80°C until required.
PDE Assays-PDE activity was assayed as described previously (38, 39) . The assays were performed at 30°C, and a freshly prepared slurry of Dowex/H 2 O/ethanol (1:1:1, v/v/v) was used. The addition of 1.2 nM MBP-PDE4D5 was shown to result in PDE activity within the linear range using 1 M cAMP substrate. 1.2 nM MBP-PDE4D5 was then assayed in the presence of His-ARB1, GST-ARB1, or GST alone at concentrations of 0.3, 3.0, 30, and 300 nM. The effect of adding boiled, denatured fusion proteins was also tested as a control.
Determination of the Relative Activity of Endogenous PDE4 Subfamilies in HEK-B2 Cells-The PDE activity of the cell lysates was measured at 1 M cAMP to give total cAMP PDE activity and also in the presence of 10 M rolipram to measure total PDE4 activity in the lysate. The relative contributions of the isoforms from each of the four PDE4 subfamilies (PDE4A, -B, -C, and -D, respectively) was determined by immunopurifying them with subfamily-specific monoclonal antibodies (ICOS Corp.). These antibodies are directed against the carboxyl-terminal regions that are conserved within the members of each subfamily but differ between the members of different subfamilies (12, 15). As we have described previously in detail (29, 40) , lysates from Hek-B2 cells were prepared in KHEM buffer, and 1 ml of lysate (500 g of protein)
was incubated with 5 l of the respective antibody and incubated at 4°C for 30 min, which is sufficient to fully and selectively immunoprecipitate all the isoforms from a particular PDE4 subfamily. Protein G-agarose beads (50 l; Amersham Biosciences) were added and incubated at 4°C for 1 h, centrifuged for 1,000 ϫ g for 3 min, washed three times in KHEM buffer, and then assayed for PDE4 activity as described above. In parallel experiments, we determined that no PDE4 activity was associated nonspecifically with the beads when no PDE4 antibody was added.
Analysis of ␤-Arrestin-PDE4D Interactions by Two-hybrid AssayThe full-length cDNAs of PDE4D3 and PDE4D5 or various truncations of PDE4D5 were cloned into the NotI site of pLEXAN (32) to express fusions between the DNA-binding domain of the E. coli LexA protein and the amino terminus of the protein encoded by the insert. The full-length cDNAs of ␤-arrestin 1, ␤-arrestin 2, or various truncations of ␤-arrestin 2, were cloned into the NotI site of pGADN (32) to express fusions between the activation domain of the Saccharomyces cerevisiae GAL4 protein and the amino terminus of the protein encoded by the insert. Two-hybrid filter ␤-galactosidase assays were performed in S. cerevisiae strain L40, as described previously (32) .
Site-directed Mutagenesis-This was performed using the circular mutagenesis method (41) . All mutagenesis and deletion constructs were confirmed by DNA sequencing prior to use.
SDS-PAGE and Immunoblotting-8% acrylamide gels were used, and the samples were boiled for 5 min after being resuspended in Laemmli buffer (36) . Gels were run at 8 mA/gel overnight or 50 mA/gel for 4 -5 h with cooling. For detection of recombinant PDEs by immunoblotting, 2-50-g protein samples were separated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted using the indicated specific antisera. Labeled bands were identified using peroxidase linked to either anti-rabbit or anti-mouse IgG, and the Amersham Biosciences ECL immunoblotting kit was used for visualization. Densitometric analysis of autoradiographs and PhosphorImager plates was used for quantitation. All quantitation was performed under conditions where we have previously obtained linear responses (25, 26, 30) .
Protein Analysis-Protein concentration was determined by the Bradford method, using bovine serum albumin as a standard (36) .
RESULTS
␤ 2 -Adrenergic Agonist-mediated Membrane Recruitment of Endogenous PDE4D3 and PDE4D5 in Hek-B2 Cells-It is well documented that stimulation of the ␤ 2 AR causes the transient recruitment of ␤-arrestin 1 and ␤-arrestin 2 to the plasma membrane (2, 5-7, 42, 43) . This is also evident in Hek293 cells transfected to express a recombinant ␤ 2 AR tagged with GFP (Hek-B2 cells) so as to slow down the kinetics of the transient recruitment of ␤-arrestin in order to facilitate biochemical investigation (31) . In Hek-B2 cells, challenge with the ␤-adrenergic agonist isoproterenol has been shown to cause the recruitment of both ␤-arrestin 1 and ␤-arrestin 2 to the membrane fraction in concert with the transfected PDE4D3 isoform (25) . In the present study, we demonstrated that treatment of intact Hek-B2 cells with isoproterenol caused the transient recruitment of endogenous PDE4D3 and PDE4D5 to the membrane (P2) fraction (Fig. 1a) . It was evident, however, that the amount of PDE4D5 recruited to the membrane fraction was greater than PDE4D3 (Fig. 1a) , with ϳ80% of the recruited protein being PDE4D5 (Fig. 1, b and c) . This ratio was near constant across the 2-12-min time course that spanned the transient recruitment of these PDE4D isoforms (Fig. 1, b and  c) . In stark contrast, PDE4D5 accounted for only 40% of PDE4D protein in total cell lysates, about 50% of PDE4D protein in the membrane fraction of untreated cells (Fig. 1b) , and a similar proportion in the high speed supernatant (S2) fraction of untreated cells.
Lysates from Hek-B2 cells had a specific activity of 35 Ϯ 3 pmol of cAMP hydrolyzed/min/mg of protein. Treatment of lysates with the PDE4-specific inhibitor rolipram (10 M) indicated that 68 Ϯ 4% of this activity was from PDE4s. Selective immunopurification, using a PDE4D-specific antibody, showed that endogenous PDE4D isoforms contributed the predominant PDE4 activity in Hek-B2 cells (66 Ϯ 4% of the total; mean Ϯ S.D., n ϭ 3). Similar selective immunopurification showed that PDE4B isoforms contributed 25 Ϯ 3% of PDE4 activity, whereas PDE4A isoforms contributed 9 Ϯ 3% of activity, with no contribution from PDE4C isoforms (Ͻ4% of total). Immunoblotting of lysates from these cells with a PDE4D-specific antibody identified only two immunoreactive bands (Fig. 2a) , namely PDE4D3 (95 kDa) and PDE4D5 (105 kDa), which comigrated with recombinant standards (data not shown). Thus, despite the fact that PDE4D3 was the major PDE4 isoform in Hek-B2 cells, it is PDE4D5 that was preferentially recruited to the membrane fraction upon isoproterenol challenge (Fig. 1) .
Interaction of Endogenous PDE4D3 and PDE4D5 with ␤-Arrestins in Various Cell Types-To extend our observations, we determined the relative levels of association of endogenous PDE4D isoforms with ␤-arrestins immunopurified from the cytosolic (S2) fractions of various cell types. First, we analyzed ␤-arrestin immunoprecipitates from Hek-B2 cells by immunoblotting with a PDE4D-specific antibody. We saw clearly that PDE4D5, rather than PDE4D3, is the predominant isoform associated with ␤-arrestins in Hek-B2 cells (Fig. 2a) . Indeed, PDE4D5 contributes about 80% of the total PDE4D that is associated with immunopurified ␤-arrestins (Fig. 2e) , a value that parallels that seen upon isoproterenol-induced membrane recruitment of these PDE4D isoforms (Fig. 1b) . We then probed for PDE4D isoforms associated with immunopurified ␤-arrestins from COS1 and A549 cells, as well as primary cardiac This ratio is given for PDE4D5 as a percentage of the combined PDE4D5 and PDE4D3 levels (mean Ϯ S.D.; n ϭ 3). c shows the timedependent recruitment of both PDE4D3 and PDE4D5 to the membrane fraction after treatment of the cells with isoproterenol. The data were derived from densitometric traces of replicate experiments (mean Ϯ S.D.; n ϭ 3). The amounts of protein translocated to the membrane are shown relative to that of PDE4D5 (set at unity) at time 0. Note that at time 0, the levels of PDE4D3 and PDE4D5 in membranes are approximately equal. myocytes (Fig. 2, b-d) . In all instances, we noted two PDE4D immunoreactive bands in cell lysates, which co-migrated with recombinant PDE4D3 and PDE4D5 standards. The amount of PDE4D5 in the various cell types varied from around 15% to around 50% of the total PDE4D (Fig. 2e) . In each case, however, we saw a preponderance of PDE4D5 (around 80%) associated with immunopurified ␤-arrestins (Fig. 2, b-e) . No PDE4D isoforms were detected in immunoprecipitates generated with a preimmune antiserum rather than one specific for ␤-arrestins (Fig. 2, a-d) . Note that in each of the cell types studied here, PDE4D3 and PDE4D5 are the only immunoreactive PDE4D bands detected in either cell lysates or in immunoprecipitates of ␤-arrestins. Thus, other PDE4D isoforms are either not expressed in these cells or are present at levels that are less than 10% those of PDE4D3/5 in lysates.
Identification of Two Regions within PDE4D5 That Are Required for Its Interaction with ␤-Arrestin-It has been demonstrated (25) that ␤-arrestins can interact with isoforms from all four PDE4 subfamilies through their highly conserved core catalytic region, which is located in the carboxyl-terminal half of the protein (Fig. 3a, top) . The novel data we present here, however, identify a preferential interaction between ␤-arrestins and the PDE4D5 isoform, at least compared with PDE4D3. PDE4D5 has an amino-terminal region of 88 amino acids that distinguishes it from all other PDE isoforms, and PDE4D3 differs from PDE4D5 only in that it has a different unique amino-terminal region of, in its case, 16 amino acids (Fig. 3a) (27) . This suggests that preferential interaction of ␤-arrestins with PDE4D5 might be dependent, either directly or indirectly, upon its unique amino-terminal region. To address this, we analyzed the effect of progressive amino-terminal truncation of PDE4D5 upon its ability to interact with ␤-arrestin 2 (Fig. 3b) . These studies were performed with recombinant forms of PDE4D5 and ␤-arrestin 2. To ensure comparable expression of these recombinant PDE4D5 forms, we co-transfected Hek293 cells with FLAG-tagged ␤-arrestin 2 and the indicated truncates of VSV epitope-tagged PDE4D5 under conditions that allowed for equal expression levels of the various PDE4D5 truncates and of ␤-arrestin 2. The input for each experiment consisted of equal levels of the indicated recombinant PDE4D5 constructs in lysates, as identified by a VSV-specific antibody, and equal levels of the indicated recombinant ␤-arrestin 2 construct (Fig. 3b, top and middle) . The output of each experiment was recorded by similarly probing anti-FLAG immunoprecipitates of recombinant ␤-arrestin 2 with the VSV-specific antibody to detect the indicated PDE4D5 truncate (Fig. 3b, bottom) . We also compared such analyses with VSV-tagged PDE4D3 (Fig. 3c) . These experiments clearly showed that loss of amino acids 1-69 of PDE4D5 has little, if any, effect on its interaction with ␤-arrestin 2 (Fig. 3, b and c) . However, further truncation, which removed the entire PDE4D5 unique amino-terminal region, caused a drop in output signal to the level seen with intact PDE4D3 (Fig. 3, b and  c, truncate N89) . Thus, the 70 -88 region of PDE4D5 (Fig. 3a) appears to contain a site that is involved in facilitating the interaction of this isoform with ␤-arrestin.
We set out to obtain independent confirmation of this result with a two-hybrid assay, using methods (32) very similar to those we have employed extensively in the past (Fig. 4) . To maximize the signal/noise ratio, in order to detect a selective PDE4D5 effect, we chose an incubation time for our assays so that little or no signal was evident for PDE4D3 with either ␤-arrestin 1 or ␤-arrestin 2, whereas a robust signal was evident for PDE4D5 (Fig. 4) . Using this approach, we clearly see confirmation of the biochemical data, with robust signals evident for PDE4D5 truncates up to and including amino acid 69 and then near ablation upon removal of the entire 88-amino acid amino-terminal region (Fig. 4a) .
Interestingly, however, when we tested the unique aminoterminal region of PDE4D5 alone for interaction with these two ␤-arrestins, we failed to see a strong positive signal (Fig. 4a,  1-88 ). This suggests that the robust nature of the signal ob- 
isoforms (a-d).
Lysates were then subjected to immunoprecipitation with either an antibody specific for ␤-arrestin 2 or preimmune serum. In each case, the immunoprecipitates (ippt) were then probed with the PDE4D-specific antibody. The ratio of PDE4D5 to PDE4D3 in the S2 fraction and the ␤-arrestin 2 immunoprecipitates is shown in each case for PDE4D5 (panel e) as a percentage of the combined PDE4D5 and PDE4D3 levels (mean Ϯ S.D.; n ϭ 3).
FIG. 3. Interaction sites on PDE4D5 for ␤-arrestin 2:
Co-immunoprecipitations. a shows a schematic representation of PDE4D5, indicating its unique amino-terminal region (amino acids 1-88), its regulatory UCR1/2 and linker LR1/2 (amino acids 89 -296), its catalytic region (amino acids 297-683), and the carboxyl-terminal region (amino acids 684 -749) unique to PDE4D isoforms. The arrows indicate the amino acids at which truncates were made for use in this study. Also shown are the two regions identified in this study to encompass interaction sites for ␤-arrestin. In the middle is shown the sequence of the unique amino-terminal of PDE4D5, with the regions required for interaction with RACK1 (32, 46) and ␤-arrestins. At the bottom is shown a sequence alignment of portions of the carboxyl-terminal regions of the PDE4D5, PDE4A5, PDE4B1, and PDE4C2 proteins (GenBank™ accession numbers AF012073, L27057, L20966, and U88712, respectively). Areas of sequence homology between these regions, which are likely to define a common point of interaction with ␤-arrestins, are underlined. Also shown is the sequence of the unique amino-terminal region of PDE4D3. b shows co-immunoprecipitations done with anti-FLAG antibody on Hek293 cells co-transfected with FLAG-tagged ␤-arrestin 2 and a VSV-tagged PDE4D construct. The co-immunoprecipitations were immunoblotted with an anti-VSV antibody to identify the transfected recombinant PDE4D constructs. The PDE4D constructs used were full-length forms of PDE4D5 (D5) and PDE4D3 (D3) as well as various amino-terminal truncations (N10, N50, N70, and N89) of PDE4D5, as in a. Also shown are the input lysates, which are equivalent in each case, and the VSV immunoblots of the output ␤-arrestin 2 immunoprecipitates. Levels of ␤-arrestin 2 in both input and output for all forms were similarly identical in these experiments, as shown by immunoblotting with an antibody to the FLAG epitope encoded by the ␤-arrestin 2 construct. c shows the quantification (percentage) of the output PDE4D relative to that for PDE4D5 for the experiments in b; mean Ϯ S.D.; n ϭ 3 separate experiments. tained in two-hybrid assays for the interaction of PDE4D5 with ␤-arrestins requires two sites, one within its unique aminoterminal region and one within the common PDE4 catalytic region.
It has been shown that PDE4 isoforms from all four subfamilies can interact with ␤-arrestins and that this is due to an interaction with their conserved catalytic domain (25) . To probe this further, we made a series of carboxyl-terminal truncations in PDE4D5 (see Fig. 3a for schematic) . Intriguingly, we found that a carboxyl-terminal truncation just into the catalytic domain caused loss of interaction with ␤-arrestin 2, as detected by two-hybrid assays performed in a manner identical to that used to test the amino-terminal region of PDE4D5 (Fig. 4b ). Since homology with PDE4 enzymes from other subfamilies extends to amino acid 683 in PDE4D5, we suggest that the core "common" PDE4 site for interaction with ␤-arrestin lies within a very small region at the carboxyl-terminal end of the catalytic domain, specifically between amino acids 662 and 683 in PDE4D5. This region in PDE4D shows strong homology with the corresponding regions in each of the other three PDE4 subfamilies (Fig. 3a, bottom) .
Identification of Two Regions in ␤-Arrestin That Are Involved in Its Binding to PDE4D5-␤-Arrestins
have been shown to act as molecular scaffolds for a variety of proteins (5) (6) (7) 43) . Analysis of the ␤-arrestin 1 crystal structure (44) shows it to be composed of two major regions, known as the N-and C-domains, each of which is composed of a seven-strand ␤-sandwich (Fig. 5a ). These regions are considered to have distinct functional attributes (44) . The N-domain binds to appropriate phosphorylated GPCRs and SRC, whereas the C-domain is involved in binding to JNK3, clathrin, and the ␤ 2 -adaptin subunit of the AP2 complex. Using our two-hybrid approach, we attempted to gain insight into the site(s) on ␤-arrestin 2 required for its interaction with PDE4D5. Removal of amino acids 1-28 of ␤-arrestin 2, which consist of a paired ␤-sheet, ablates the ability of ␤-arrestin 2 to bind PDE4D5 (Fig. 5b) . In addition to this, mutation to the neutral alanine of either of two pairs of positively charged lysines located within this portion of the N-domain of ␤-arrestin 2, namely K11A/K12A or K25A/R26A, totally blocked its interaction with PDE4D5 (Fig. 5c) . This is consistent with the deletion analysis, which identifies the importance of the first 28 amino acids of ␤-arrestin 2 in its interaction with PDE4D5.
We then analyzed the C-domain of ␤-arrestin 2 and showed that a large deletion, of amino acids 255-418, did not affect its ability to interact with PDE4D5 in two-hybrid assays (Fig. 5b) . However, further carboxyl-terminal truncation of ␤-arrestin 2, up to amino acid 192, blocked its interaction with PDE4D5 (Fig. 5b) . This suggests that the 192-255 region of ␤-arrestin 2 is also required for its interaction with PDE4D5. It has been shown previously that a mutation within this region of rat ␤-arrestin 2 (Arg 196 -Arg 197 -Ser 198 to KP) blocks its interaction with JNK3 (45) . We generated the corresponding mutation in human ␤-arrestin 2 (R196K/S197P) and showed that it interacted similarly to wild type ␤-arrestin 2 with PDE4D5 in this assay (Fig. 5d) .
We also evaluated mutations of ␤-arrestin 2 in immunoprecipitation experiments. We found that truncation of either of the N-and C-terminal portions of ␤-arrestin 2 (1-192 and 28 -418 truncations) (Fig. 5, e and f) severely attenuated its interaction with PDE4D5. In addition, we showed that the K25A/R26A mutation of ␤-arrestin 2 profoundly attenuated its ability to interact with PDE4D5 (Fig. 5, e and f) . Both of these observations were consistent with results obtained with twohybrid assays. However, in the biochemical studies, we did observe some residual binding, possibly because we were disrupting only one of two binding sites in each instance (see "Discussion"). This residual interaction may not have been detected in the two-hybrid assays, possibly because of different thresholds for a positive interaction between the two assays.
Thus, two regions of ␤-arrestin 2 appear to be needed for it to interact with PDE4D5, one within the extreme amino-terminal region of the N-domain and the other within the amino-terminal half of the C-domain.
␤-Arrestin Does Not Affect the Enzymatic Activity of PDE4D5-It has been shown previously that PDE4D5 and ␤-arrestin 1, expressed as fusion proteins in E. coli, can be purified to apparent homogeneity and shown to interact with each other in pull-down assays (25) . We assessed the action of purified His-tagged ␤-arrestin 1 on the activity of PDE4D5, produced as a MBP fusion protein (see "Experimental Procedures"). Both fusions were purified to apparent homogeneity on SDS-PAGE, as we have described before (25, 32) , with MBP-PDE4D5 having a specific activity of around 200 nmol/mg/min protein, assayed at 1 M cAMP. The addition of 30 nM Histagged ␤-arrestin 1 sufficed to pull down the entire pool of FIG. 4 . Interaction sites on PDE4D5 for ␤-arrestin 2: Two-hybrid studies. a, various constructs encoding amino-terminal truncations of PDE4D5 were tested for their ability to interact with ␤-arrestin 1 (␤-ARR1) and ␤-arrestin 2 (␤-ARR2), using a yeast two-hybrid filter ␤-galactosidase assay. The PDE4D5 truncations were cloned into pLEXAN to generate DNA-binding domain fusions, and the ␤-arrestins were cloned into pGADN to generate activation domain fusions. b, various constructs encoding carboxyl-terminal truncations of PDE4D5 were cloned into pLEXAN and tested for their ability to bind ␤-arrestin 2. Also shown are standards for the assays, namely the oncoproteins Ras v12 and RAF, which produce blue patches, or the vectors without inserts, which remain pink (32) . These data reflect experiments typical of ones done at least three times.
MBP-PDE4D5 (1.2 nM; data not shown). However, the addition of His-tagged ␤-arrestin 1 at 0.3, 3.0, 30, and 300 nM to assays containing 1.2 nM MBP-PDE4D5 had no discernible effect (Ͻ8% change) on the activity of PDE4D5, assayed at 1 M cAMP. This suggests that the binding of ␤-arrestin 1 to PDE4D5 does not affect its catalytic activity. We obtained a similar negative effect, namely Ͻ9% change in PDE4D5 activity, using GST-tagged ␤-arrestin 1, over an identical range of concentrations.
DISCUSSION
The phosphorylation of GPCRs by G-protein receptor-coupled kinase and subsequent recruitment of ␤-arrestins play a key role in the desensitization mechanisms associated with GPCRs (2, 5-7, 42, 43) . The recruited ␤-arrestins serve not only to inhibit sterically the coupling of GPCRs to their appropriate G-protein but also, by virtue of their acting as adaptor proteins, recruit other regulatory molecules to the transmembrane re- (45) . b-d, yeast two-hybrid filter ␤-galactosidase assays. b, various regions of ␤-arrestin 2 were tested for their ability to interact with full-length PDE4D5. c and d, experiments examining various indicated "point" mutants of ␤-arrestin 2, as described under "Experimental Procedures." These data all reflect experiments typical of ones done at least three times. e, immunoprecipitations from the high speed supernatant (S2) fraction of COS1 cells co-transfected with various truncations or mutants of ␤-arrestin 2 (all with a carboxyl-terminal FLAG tag) and various truncations or mutants of PDE4D5 (all with a carboxyl-terminal VSV tag). The immunoprecipitations were performed with the anti-FLAG antibody and then immunoblotted with the VSV antibody, to assess the interactions (panel e, top) or the FLAG antibody, to ensure that an equal amount of ␤-arrestin 2 was present in the fractions (panel e, bottom). To ensure that equal amounts of PDE4D5 were present in the fractions, they were immunoblotted with the VSV antibody (panel e, middle). Equal amounts of protein (50 g) were loaded in each lane. f, a quantitation of these data, performed by densitometric analysis (means Ϯ S.D., n ϭ 3).
ceptor. Indeed, it has been shown recently that ␤-arrestins can bind to members of all four PDE4 cAMP-specific phosphodiesterase subfamilies by an interaction involving their highly conserved catalytic unit (25) . Through such an interaction, PDE4 isoforms can be recruited to the ␤ 2 AR upon its stimulation by the agonist, isoproterenol (25) . This allows a functional PDE4 to be delivered to the site of cAMP synthesis in the plasma membrane.
PDE4D enzymes are the major PDE4 isoforms found in a wide variety of cells, with the PDE4D3 and PDE4D5 long isoforms predominating (12, 13, 15, 27) . In Hek-B2 cells, challenge with isoproterenol has been shown (25) to cause the ␤-arrestin-dependent translocation of PDE4 isoforms to the ␤ 2 AR associated with the membrane fraction. Whereas in these cells the total cellular level of PDE4D3 is greater than that of PDE4D5, challenge of these cells with isoproterenol causes the level of PDE4D5 that is translocated to the membrane fraction to exceed that of PDE4D3 (Fig. 1) . In this study we demonstrate, in various cell types, that PDE4D5 is found preferentially complexed with ␤-arrestins (Fig. 2) , with levels of PDE4D5 exceeding those of PDE4D3 in complexes with immunopurified ␤-arrestins (Fig. 2) . This is also evident in cell types where the total cellular level of PDE4D3 exceeded that of PDE4D5 (Fig. 2) . This implies that PDE4D5 may interact more strongly than PDE4D3 with ␤-arrestins in these cells, although we cannot totally exclude the possibility, in these particular experiments, that other factors may also contribute to the differential interaction of these isoforms with ␤-arrestins. Nonetheless, we believe that when isoproterenol treatment of HEK-B2 cells causes the preferential recruitment to the membrane fraction of PDE4D5, compared with PDE4D3, the simplest explanation is that it reflects the preferential interaction of PDE4D5 with the agonist-recruited ␤-arrestins that we have identified here.
It has been demonstrated that the core catalytic unit of PDE4D3, which is very highly conserved among all four PDE4 subfamilies, interacts with ␤-arrestins (25, 26) . This is presumed to explain why members from all four PDE4 subfamilies are able to interact with ␤-arrestins (25, 26) . Here, using both biochemical and two-hybrid approaches, we show that the unique 88-amino acid amino-terminal region of PDE4D5 confers its heightened ability to interact with ␤-arrestins (Figs. 3  and 4) . Specifically, the interaction site appears to be located within amino acids 70 -88 of PDE4D5. However, when the unique amino-terminal region of PDE4D5 was tested in isolation for interaction with ␤-arrestin in two-hybrid assays, it failed to yield a strong positive signal (Fig. 4) , indicating that the robust nature of the interaction of PDE4D5 with ␤-arrestins requires both its unique amino-terminal region and a portion of the common PDE4 catalytic domain. Intriguingly, we have shown previously (32) that PDE4D5 interacts with RACK1 and that this interaction also requires the unique amino-terminal region of PDE4D5. However, the precise regions of PDE4D5 needed for its interaction with RACK1 are different from those required for it to interact with ␤-arrestin. A single region within the PDE4D5 amino terminus (amino acids 12-49) is sufficient for the interaction of RACK1 and PDE4D5 (32, 46) , whereas two different regions of PDE4D5 are needed for it to interact with ␤-arrestin (Fig. 3a) . Whether the amino-terminal region of PDE4D5 provides a binding site per se with ␤-arrestin or whether it facilitates the functioning of the "common" site located within the PDE4 catalytic region remains to be determined. Indeed, it may even serve to interact with other proteins that, in turn, facilitate ␤-arrestin binding. ␤-arrestin, however, appears to act simply as a scaffold in recruiting PDE4D5, since it exerts no discernible effect on the activity of this enzyme.
The crystal structure of ␤-arrestin 1 has been determined (44) . ␤-Arrestin is formed from two major domains, called the N-and C-domains, each of which is composed of a seven-strand ␤-sandwich. The N-domain is responsible for binding to appropriate GPCRs when they are phosphorylated. However, ␤-arrestins can act as a multifunctional adapter proteins and it has been shown that SRC and Ask1 can bind to the N-domain, whereas JNK3, IP6, NSF, clathrin, and AP2 can bind to the C-domain (5-7, 43, 45, 47) . Using a truncation strategy, we show here that amino-terminal portions of both the N-and C-domains are required for the binding of PDE4D5 (Fig. 5) . The crystal structure of ␤-arrestin 1 (44) indicates that these two regions do not juxtapose each other. One possibility is that they may provide distinct sites for interaction with the two regions in PDE4D5 shown here to confer interaction with ␤-arrestin. One of the two regions in ␤-arrestin 2, located within amino acids 1-28, contains two pairs of positively charged amino acids, namely Lys 11 /Lys 12 and Lys 25 /Arg 26 , which are located at the ends of distinct ␤-sheets in ␤-arrestin 1 (44) . The mutation of these amino acids to the neutral alanine ablates the ability of ␤-arrestin 2 to interact with PDE4D5 (Fig. 5c ), emphasizing the importance of this subregion for binding. Within each of these pairs, the positively charged side chains of the two adjacent amino acids extend out from opposing surfaces of their corresponding ␤-sheets (44) . However, it is only the side chain of K11 that is free and exposed to solvent, whereas others are involved in internal interactions (44 (44) . These various positively charged amino acids appear to play a key role in determining interactions not only within the N-domain itself but also between the N-and C-domains. These interactions appear to be functionally important, since the binding of ␤-arrestin to PDE4D5 is blocked upon mutation of each of these pairs to the neutral alanine.
The second region in ␤-arrestin involved in its interaction with PDE4D5 lies between amino acids 192 and 255 (Fig. 5b) . Whereas this region has been highlighted as being important for the binding of JNK3 to ␤-arrestin 2 (45), our analysis of the R196K/S197P mutation, which blocks ␤-arrestin interaction with JNK3, shows that it does not affect the interaction of ␤-arrestin 2 with PDE4D5 (Fig. 5d ). This indicates that PDE4D5 and JNK3 bind to ␤-arrestin 2 in different ways.
An important area for further investigation is the regulation of binding of PDE4D5 to ␤-arrestin. Conti and co-workers, together with ourselves (37, 48 -51) , have shown that the long PDE4 isoforms are phosphorylated at a serine located at the beginning of UCR1 (Ser 54 in PDE4D3; Ser 126 in PDE4D5) and that this activates these isoforms. PDE4 enzymes are also phosphorylated by extracellular signal-regulated kinase 2, at a site located in the catalytic domain (Ser 579 in PDE4D3; Ser 651 in PDE4D5), and this inhibits enzyme activity (52) (53) (54) . Given that agonist stimulation of the ␤ 2 AR activates both the cAMP and extracellular signal-regulated kinase 2 signaling pathways (2, 3, 5-7), it would be intriguing if the phosphorylation status of PDE4D5 could alter its interaction with ␤-arrestin. Such regulation could have potential pharmacological implications, in view of the many known inhibitors of the components of the signal transduction pathways that involve these kinases. PDE4 isoforms are widely distributed in cells, where they are expressed at different relative levels (12, 13, 15) . It has previously been surmised (25) that the ␤-arrestin scaffolds would bind a proportional fraction of these. However, our studies indicate that in cells where the PDE4D5 isoform is expressed, it is likely to be preferentially associated with ␤-arrestins. This is because PDE4D5 possesses two sites for interaction with ␤-arrestin, one located within the conserved catalytic domain and the second located within the unique PDE4D5 aminoterminal region. This suggests that PDE4D5 is poised to play a key role in regulating the functioning of GPCRs, such as the ␤ 2 AR.
